Hong Kong Retail Distributors Stock News

Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China in exchange for an upfront US$650 million payment plus very large potential milestone payments and tiered double-digit royalties. The deal not only validates RemeGen’s oncology platform but also links RC148 to AbbVie’s antibody-drug conjugate pipeline, broadening future combination therapy...

If you are wondering whether Lenovo Group's current share price lines up with its underlying value, this breakdown is designed to give you a clear, numbers first view. Lenovo's shares last closed at HK$8.84, with returns of 0.5% decline over 7 days, 5.2% decline over 30 days, 7.4% decline year to date and 3.0% decline over the past year, set against longer term returns of 58.5% over 3 years and 20.1% over 5 years. Those mixed returns have arrived as Lenovo continues to attract attention in...

Leadership change and why it matters for China Unicom (Hong Kong) China Unicom (Hong Kong) (SEHK:762) has appointed Dong Xin as both Chairman and Chief Executive Officer, a dual role that often prompts investors to reassess how leadership, governance and execution might align. See our latest analysis for China Unicom (Hong Kong). At a share price of HK$7.77, China Unicom (Hong Kong) has a 1-day share price return of 1.97%, while the 90-day share price return of 17.25% decline sits alongside a...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...

With a price-to-earnings (or "P/E") ratio of 17.6x Shangri-La Asia Limited ( HKG:69 ) may be sending bearish signals at...

Why XtalPi Holdings Is On Investors’ Radar Today XtalPi Holdings (SEHK:2228) is drawing fresh attention as its AI powered drug discovery services support robust revenue growth and key healthcare AI partnerships, while some investors remain cautious about margins and cash flow. See our latest analysis for XtalPi Holdings. That stronger interest is showing up in the numbers, with a 1 month share price return of 41.89% at a latest share price of HK$13.48 and a 1 year total shareholder return of...

Dispatch Bio and CARsgen Therapeutics Holdings announced a clinical collaboration to run a Phase 1 trial in China evaluating DISP-11, combining Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevorcabtagene autoleucel in patients with epithelial solid tumors. This pairing of a tumor-specific virus that “paints” a synthetic antigen with an existing CAR T-cell therapy aims to open an immunotherapy path for solid tumors, where treatment options...

China Next-Gen Commerce and Supply Chain FY 2025 earnings snapshot China Next-Gen Commerce and Supply Chain (SEHK:3928) has posted its FY 2025 numbers with second half revenue of S$29.7 million and a net loss of S$1.3 million, translating to basic EPS of S$0.002694 loss. The company has seen revenue move from S$32.3 million in 2H FY 2024 to S$29.7 million in 2H FY 2025, while EPS shifted from a S$0.002157 loss to a S$0.002694 loss over the same period, which sets a cautious backdrop for how...

China Nonferrous Mining Corporation Limited recently reported that rehabilitation of the main and auxiliary shafts at Chambishi Southeast Mine was completed in December 2025, allowing the operation to resume full production on 1 January 2026. Alongside this, the company issued 2026 production guidance outlining approximately 484,000 tonnes of overall copper output and diversified by-products, giving investors clearer visibility into future operating volumes and product mix. We will now...

Investors who take an interest in Chuanglian Holdings Limited ( HKG:2371 ) should definitely note that insider Xing Lu...

From what we can see, insiders were net sellers in Laekna, Inc.'s ( HKG:2105 ) during the past 12 months. That is...

Let's talk about the popular JD Health International Inc. ( HKG:6618 ). The company's shares saw a double-digit share...

From what we can see, insiders were net buyers in Jacobio Pharmaceuticals Group Co., Ltd.'s ( HKG:1167 ) during the...

Insiders were net buyers of Minieye Technology Co., Ltd's ( HKG:2431 ) stock during the past year. That is, insiders...

You may think that with a price-to-sales (or "P/S") ratio of 8.4x Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) is...

Jiangxi Copper (SEHK:358) has signed multi year procurement and sales cooperation agreements with China Ordins Group, covering mutual supply of copper, nickel, aluminium, zinc, tin and other metals under market based pricing from 2026 to 2028. See our latest analysis for Jiangxi Copper. The new multi year agreements arrive after a strong run in the shares, with a 30 day share price return of 21.43% and a 90 day share price return of 34.58%. The 1 year total shareholder return of around 3.7x...

MMG Limited recently reported its fourth-quarter and full-year 2025 production results alongside detailed 2026 production and C1 cost guidance for its major copper and zinc operations, including Las Bambas, Kinsevere, Khoemacau, Dugald River and Rosebery. A distinctive feature of the update is Rosebery’s 2026 C1 cost outlook, where by-product credits are expected to drive zinc cash costs below zero on a per‑pound basis. We’ll now examine how MMG’s 2026 cost and production guidance,...

Tiangong International announced that its subsidiary Jiangsu Tiangong Aihe Technology was approved on 16 January 2026 to join the Institute of Energy, Hefei Comprehensive National Science Center’s joint laboratory for developing fusion-oriented advanced metallic materials, including large-scale powder metallurgy 304B7 high-boron steel and new neutron shield steel. This collaboration gives Tiangong direct involvement in controlled nuclear fusion material research, potentially broadening...

China International Capital (SEHK:3908) has announced a series of senior leadership changes, including the appointment of a new Chief Financial Officer and a new Secretary to the Board, as part of efforts to maintain its governance structure. See our latest analysis for China International Capital. At a share price of HK$21.24, China International Capital has a 1 month share price return of 5.67% and a 1 year total shareholder return of 61.85%, while the 3 year total shareholder return of...

Ascletis Pharma (SEHK:1672) has attracted fresh attention after announcing ASC37, a once-monthly subcutaneous GLP-1R/GIPR/GCGR triple agonist for cardiometabolic diseases, discovered using its AI assisted and ultra long acting peptide platforms. See our latest analysis for Ascletis Pharma. The ASC37 announcement lands after a strong run in the shares, with a 90 day share price return of 56.58% and a year to date share price return of 23.96%. The 1 year total shareholder return of 249.14%...

Blue Moon Group Holdings (SEHK:6993) issued new earnings guidance, telling investors it expects at least a 50% reduction in its 2025 loss compared with the HK$749.3 million loss recorded for 2024. See our latest analysis for Blue Moon Group Holdings. That guidance landed alongside a 1 day share price return of 4.56% and a year to date share price return of 8.76% at HK$2.98. However, the 1 year total shareholder return of 13.58% and 5 year total shareholder return of 77.98% show that longer...

Why Sihuan Pharmaceutical’s latest filler approval matters for investors Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that six additional specifications of its polylactic acid facial filler received approval from China’s National Medical Products Administration, expanding its medical aesthetics product range to allow more tailored anti aging treatments. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The latest PLLA filler approvals come after a strong...

Chinese regulators have given Tencent Holdings (SEHK:700) and other large tech groups preliminary approval to prepare purchases of Nvidia's H200 AI chips. The in principle clearance signals possible progress on access to advanced AI hardware for Tencent within China’s existing controls on sensitive technology imports. Tencent recently reiterated its focus on AI development and open ecosystem partnerships at the World Economic Forum. Tencent is a major Chinese technology company with...